Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211874
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Revenue | $6,229 | $158,569 |
| Operating expenses: | ||
| Research and development | 39,673 | 32,676 |
| Sales, general and administrative | 19,974 | 14,653 |
| Total operating expenses | 59,647 | 47,329 |
| (Loss) income from operations | (53,418) | 111,240 |
| Other income (expense): | ||
| Interest income (expense), net | 3,397 | 2,889 |
Item 1. Financial Statements.
FAQ
- What is Stoke Therapeutics, Inc.'s R&D?
- Stoke Therapeutics, Inc. (STOK) reported R&D of $39.67M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s R&D changed year-over-year?
- Stoke Therapeutics, Inc.'s R&D increased by 21.4% year-over-year, from $32.68M to $39.67M.
- What is the long-term trend for Stoke Therapeutics, Inc.'s R&D?
- Over 4 years (2021 to 2025), Stoke Therapeutics, Inc.'s R&D has grown at a 26.3% compound annual growth rate (CAGR), from $54.17M to $137.92M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Stoke Therapeutics, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude